Cardiol Therapeutics Inc. (CRDL)
NASDAQ: CRDL · Real-Time Price · USD
1.280
-0.030 (-2.29%)
Dec 20, 2024, 4:00 PM EST - Market closed
Company Description
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases.
Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure.
It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Cardiol Therapeutics Inc.
| Country | Canada |
| Founded | 2017 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 6 |
| CEO | David Elsley |
Contact Details
Address: 2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5 Canada | |
| Phone | 289-910-0850 |
| Website | cardiolrx.com |
Stock Details
| Ticker Symbol | CRDL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| CIK Code | 0001702123 |
| CUSIP Number | 14161Y200 |
| ISIN Number | CA14161Y2006 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| David G. Elsley MBA | President, Chief Executive Officer and Director |
| Christopher J. Waddick C.A., C.M.A., CPA, CMA, MBA | Chief Financial Officer, Corporate Secretary and Director |
| Bernard Lim B.Sc. | Chief Operating Officer |
| Dr. Andrew Warwick Hamer M.D. | Chief Medical Officer and Head of Research & Development |
| Trevor Burns | Investor Relations |
| John A. Geddes BSCPT, MBA | Vice President of Corporate Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 18, 2024 | 6-K | Report of foreign issuer |
| Nov 14, 2024 | 6-K | Report of foreign issuer |
| Nov 6, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 22, 2024 | 6-K | Report of foreign issuer |
| Oct 11, 2024 | 6-K | Report of foreign issuer |
| Oct 10, 2024 | 6-K | Report of foreign issuer |
| Oct 9, 2024 | SUPPL | Filing |
| Oct 9, 2024 | 6-K | Report of foreign issuer |
| Oct 8, 2024 | 6-K | Report of foreign issuer |
| Oct 8, 2024 | SUPPL | Filing |